Fibroblast growth factor 23 in chronic kidney disease: New insights and clinical implications |
| |
Authors: | Damasiewicz Matthew J Toussaint Nigel D Polkinghorne Kevan R |
| |
Affiliation: | Department of Nephrology, Monash Medical Centre, Monash University, Clayton, Victoria, Australia. Matthew.Damasiewicz@monash.edu |
| |
Abstract: | Fibroblast growth factor 23 (FGF-23) is a recently discovered regulator of phosphate and mineral metabolism. Its main physiological function is the enhancement of renal phosphate excretion. FGF-23 levels are inversely related to renal function and in patients with chronic kidney disease (CKD) elevation in FGF-23 precedes the rise of serum phosphate. Studies have demonstrated an important role for FGF-23 in the development of secondary hyperparathyroidism through an effect on parathyroid hormone and calcitriol. In cross-sectional studies FGF-23 has been associated with surrogate markers of cardiovascular disease such as endothelial dysfunction and arterial stiffness. FGF-23 has also been associated with both progression of CKD and mortality in dialysis patients. The discovery of FGF-23 has provided a profound new insight into bone and mineral metabolism, and it may become an important biomarker and therapeutic target in CKD. |
| |
Keywords: | FGF‐23 vitamin D CKD‐MBD chronic kidney disease phosphate metabolism |
本文献已被 PubMed 等数据库收录! |